Becton, Dickinson and Company (NYSE:BDX) Stock Picked Up by Analysts at Wolfe Research

Analysts at Wolfe Research began coverage on shares of Becton, Dickinson and Company (NYSE:BDX) in a research note issued on Tuesday, Marketbeat Ratings reports. The brokerage set an “outperform” rating on the medical instruments supplier’s stock.

Several other analysts have also recently issued reports on the stock. Evercore set a $180.00 price objective on shares of Becton, Dickinson and Company in a research note on Monday, July 6th. TD Cowen lifted their price objective on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Wells Fargo & Company lifted their price objective on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research report on Friday, August 7th. UBS Group began coverage on Becton, Dickinson and Company in a research note on Tuesday, July 28th. They set a “buy” rating and a $190.00 price objective on the stock. Finally, Piper Sandler upped their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, August 7th. Eight equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $185.07.

Becton, Dickinson and Company Price Performance

BDX stock traded up $1.29 during midday trading on Tuesday, reaching $192.03. The stock had a trading volume of 43,036 shares, compared to its average volume of 2,452,186. Becton, Dickinson and Company has a 52-week low of $127.59 and a 52-week high of $195.99. The company has a current ratio of 0.87, a quick ratio of 0.51 and a debt-to-equity ratio of 0.55. The company’s fifty day simple moving average is $184.26 and its 200 day simple moving average is $164.00. The company has a market cap of $52.91 billion, a price-to-earnings ratio of 57.92, a price-to-earnings-growth ratio of 12.93 and a beta of 0.21.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. The business had revenue of $4.98 billion during the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, sell-side analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total transaction of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares in the company, valued at $3,717,022.80. This represents a 0.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total transaction of $440,887.92. Following the sale, the executive vice president owned 14,856 shares in the company, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 6,906 shares of company stock valued at $1,265,855 in the last ninety days. Company insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Maryland Capital Advisors Inc. lifted its holdings in Becton, Dickinson and Company by 13,900.0% in the third quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 139 shares during the period. SHP Wealth Management acquired a new position in shares of Becton, Dickinson and Company during the 4th quarter worth $26,000. Meeder Asset Management Inc. grew its stake in shares of Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 102 shares during the period. Main Street Group LTD purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at about $29,000. Finally, Bell Investment Advisors Inc purchased a new position in shares of Becton, Dickinson and Company in the 2nd quarter valued at about $29,000. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops, manufactures and sells a broad range of products used by healthcare providers, clinical laboratories, pharmaceutical companies and patients. Its offerings support medication delivery, diagnostics, infection prevention, surgical care and other clinical procedures.

BD’s products include needles, syringes, injection devices, intravenous administration systems, medication-management technologies, specimen-collection products, diagnostic systems and laboratory instruments.